skip to content
Advertisement
Premium
This is an archive article published on February 27, 2024

Roche Pharma launches multiple sclerosis treatment drug in India

The majority of individuals are diagnosed with multiple sclerosis between the ages of 20 and 40, making the disease a leading cause of non-traumatic disability in younger adults.

roche pharmaWith the new drug, Roche Pharma is expanding its neurology portfolio to cater to unmet needs of patients grappling with multiple sclerosis. (Reuters)

Roche Pharma India on Tuesday launched a drug for the treatment of Multiple Sclerosis (MS), expanding its neurology portfolio to cater to unmet needs of patients grappling with the disease.

The company has introduced Ocrevus (Ocrelizumab) which is the first and only approved disease modifying therapy for both Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS).

Patients on Ocrevus have the highest persistence and superior adherence to treatment because of its twice yearly (once every six months) dosing which is preferable for most patients compared to more frequent (monthly) injections.

Story continues below this ad

“The introduction of Ocrevus represents a pivotal moment in the management of multiple sclerosis in India,” Roche Pharma India CEO and Managing Director V Simpson Emmanuel said.

Boasting formidable efficacy, streamlined administration, and a long-term safety record, Ocrevus instils fresh optimism in individuals grappling with this formidable neurological condition, he added.

The majority of individuals are diagnosed with multiple sclerosis between the ages of 20 and 40, making the disease a leading cause of non-traumatic disability in younger adults.

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement